Search research articles
Contact Us
Filters
Showing results (391-400 of 441) with videos related to
Page
of 45
Sort By:
The Lancet. Oncology
|
July 22, 2017
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Michele Maio, Arnaud Scherpereel, Luana Calabrò, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2017
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Federica Grosso, Nicola Steele, Silvia Novello, et al.
BMJ Open
|
January 26, 2022
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial
Peey Sei Kok, Patrick M Forde, Brett Hughes, et al.
EJNMMI Research
|
June 20, 2026
Dual-time-point [<sup>18</sup>F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy
Solfrid Thunold, Eivor Hernes, Lars Tore Gyland Mikalsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2022
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
S Peters, A Scherpereel, R Cornelissen, et al.
Nature Communications
|
August 19, 2022
Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice
Rachael M Zemek, Wee Loong Chin, Vanessa S Fear, et al.
Journal of Crohn'S & Colitis
|
August 27, 2022
Analysis of Systemic Epigenetic Alterations in Inflammatory Bowel Disease: Defining Geographical, Genetic and Immune-Inflammatory influences on the Circulating Methylome
Rahul Kalla, Alex T Adams, Jan K Nowak, et al.
Cancer Causes & Control : CCC
|
February 20, 2022
Physical activity and glioma: a case-control study with follow-up for survival
Zohreh Basiri, Yi Yang, Fiona J Bruinsma, et al.
Lancet (London, England)
|
January 24, 2021
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas, Arnaud Scherpereel, Anna K Nowak, et al.
Cell Reports
|
December 28, 2022
CD4<sup>+</sup> T cells drive an inflammatory, TNF-α/IFN-rich tumor microenvironment responsive to chemotherapy
Caitlin M Tilsed, Nicola Principe, Joel Kidman, et al.
Page
of 45
Search research articles
Search
Showing results (391-400 of 441) with videos related to
Sort By:
Page
of 45
The Lancet. Oncology
|
July 22, 2017
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Michele Maio, Arnaud Scherpereel, Luana Calabrò, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2017
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Federica Grosso, Nicola Steele, Silvia Novello, et al.
BMJ Open
|
January 26, 2022
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial
Peey Sei Kok, Patrick M Forde, Brett Hughes, et al.
EJNMMI Research
|
June 20, 2026
Dual-time-point [<sup>18</sup>F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy
Solfrid Thunold, Eivor Hernes, Lars Tore Gyland Mikalsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2022
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
S Peters, A Scherpereel, R Cornelissen, et al.
Nature Communications
|
August 19, 2022
Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice
Rachael M Zemek, Wee Loong Chin, Vanessa S Fear, et al.
Journal of Crohn'S & Colitis
|
August 27, 2022
Analysis of Systemic Epigenetic Alterations in Inflammatory Bowel Disease: Defining Geographical, Genetic and Immune-Inflammatory influences on the Circulating Methylome
Rahul Kalla, Alex T Adams, Jan K Nowak, et al.
Cancer Causes & Control : CCC
|
February 20, 2022
Physical activity and glioma: a case-control study with follow-up for survival
Zohreh Basiri, Yi Yang, Fiona J Bruinsma, et al.
Lancet (London, England)
|
January 24, 2021
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas, Arnaud Scherpereel, Anna K Nowak, et al.
Cell Reports
|
December 28, 2022
CD4<sup>+</sup> T cells drive an inflammatory, TNF-α/IFN-rich tumor microenvironment responsive to chemotherapy
Caitlin M Tilsed, Nicola Principe, Joel Kidman, et al.
Page
of 45